<DOC>
	<DOCNO>NCT00974740</DOCNO>
	<brief_summary>Clinical study show immunomodulators ( like Anti-CD3 antibody ) effect beta-cell-preservation . The lipid-lowering agent atorvastatin also potent immunomodulator . In study effect 80 mg atorvastatin per day preservation beta-cell function recent onset type 1 diabetes study , determine stimulate C-peptide level .</brief_summary>
	<brief_title>DIATOR-Diabetes Intervention With Atorvastatin</brief_title>
	<detailed_description>The objective study follow : - To assess effect atorvastatin pancreatic beta-cell function measure C-peptide liquid mixed meal stimulation patient newly diagnose type 1 diabetes , - To assess effect metabolic control measure HbA1c insulin requirement , - To assess safety tolerability atorvastatin subject newly diagnose type 1 diabetes , - To assess effect risk factor diabetic complication indicate change lipid CRP , - To assess effect systemic immune abnormality measure effect beta-cell autoantibody , blood cytokine chemokines protein transcriptional level . Study duration : 18 month</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Insulin treat patient newly diagnose type 1 diabetes mellitus define ADA criterion least two week later 3 month start insulin treatment Age 18 39 year , inclusive Male patient female patient use adequate contraceptive method Tested positive least one three islet autoantibody GAD65 , IA2 ICA History malignancy Presence clinically significant hepatic renal disease , indicate , limited serum creatinine elevate ten percent upper limit normal , elevation AST ALT 3 time upper limit normal Any acute chronic condition may affect patient 's response treatment might associate increased risk patient participate , judge investigator Current use antiinflammatory immunomodulatory drug , antihypertensive , lipidlowering , antidiabetic drug insulin Pregnant nursing woman woman intend become pregnant Known suspect allergy atorvastatin component thr trial product Known myopathy , myalgia myositis serumCPK 3 time upper limit normal Patients severe blood loss ( &gt; = 400 mL , e.g . blood donation ) within 2 month prior visit 2 Any significant laboratory abnormality A serum LDLcholesterol 150 mg/dL time screen Unwillingness comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>type 1 diabetes</keyword>
</DOC>